- Michaël R Laurent, consultant geriatrician
- Imelda Hospital, Bonheiden, Belgium
- michael.laurent{at}imelda.be
In their article, Mitchell and colleagues state that the use of denosumab in men with castration sensitive metastatic prostate cancer who lack an appropriate indication (such as osteoporosis) constitutes non-recommended, low value care.1
Standard treatment for this group of patients, however, is androgen deprivation therapy, which inherently carries an increased risk …